RYR-2 antibodies are widely used in:
Cardiac Selectivity: Anti-RYR-2 antibodies show strong reactivity in heart tissue lysates but no cross-reactivity in liver or skeletal muscle (Fig. 1A, ).
Species Reactivity: Confirmed in human, mouse, and rat samples .
Calcium Regulation: RYR-2 antibodies help identify dysregulated calcium signaling in cardiac pathologies .
Autoantibody Implications: While not directly linked to RYR-2, autoantibodies to ACE2 (another cardiac protein) correlate with severe COVID-19 outcomes , highlighting the broader relevance of cardiac autoantibodies.
| Sample | Band Observed | Dilution | Exposure Time |
|---|---|---|---|
| Mouse heart lysate | 564 kDa | 1:1,000 | 15 seconds |
| HEK-293T transfected | 564 kDa | 1:1,000 | 3 seconds |
| Rat liver (negative) | No band | 1:1,000 | 37 seconds |
FNAIT Research: While RYR-2 antibodies are not directly used in fetal/neonatal alloimmune thrombocytopenia (FNAIT), monoclonal anti-HPA-1a antibodies (e.g., RLYB212) demonstrate how antibody engineering can prevent alloimmunization .
Pseudovirus Assays: Neutralization assays for SARS-CoV-2 antibodies provide methodological parallels for quantifying RYR-2 antibody efficacy.